Not expressed without acrylamide. Control animals without acrylamide. No GFP signal was detected. Animal treated with 500 mg/l acrylamide. Whole body showed strong GFP signal.
Not expressed without acrylamide. Control animals without acrylamide. No GFP signal was detected. Animal treated with 500 mg/l acrylamide. Weak GFP signal was from head, gonad, and tail regions.
Not expressed without acrylamide. Control animals without acrylamide. No GFP signal was detected. Animals treated with 500 mg/l acrylamide. A GFP signal was induced in the head, vulva, and tail regions.
Expressed constitutively without acrylamide. Control animal without acrylamide. GFP signal was constitutively detected from the intestine region. Animal treated with 500 mg/l acrylamide. Stronger GFP signal detected from the intestine region.
Expressed constitutively without acrylamide. Control animals without acrylamide; GFP signal was constitutively expressed in the head and tail regions. Animal treated with 500 mg/l acrylamide. GFP signal resembled that for the control.
Expressed constitutively without acrylamide. Control animal without acrylamide. Weak GFP signals were from the tail region. Animal treated with 500 mg/l acrylamide. GFP signal was from the head, intestine, and tail regions.
Expressed constitutively without acrylamide. Control animal without acrylamide. Weak GFP signal was from the head region. Animal treated with 500 mg/l acrylamide. GFP signal in the head region resembled that for the control.
Expressed constitutively without acrylamide. Control animals without acrylamide. GFP signal was constitutively expressed in the head and intestine region. Whole animal treated with 500 mg/l acrylamide. GFP signal was from the hypodermis.
In dvIs19, GFP signals were constitutively observed in the body-wall muscle without acrylamide. Its GFP signal pattern was the same as that for MJCU017 upon exposure to acrylamide.